<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><u><span style="font-size:12.0pt;font-family:Palatino;color:#0070C0">NIH Grant Writing Workshop – SAVE THE DATE<o:p></o:p></span></u></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The FSU Office of Research Development (ORD) is partnering with FAMU to offer a free two day intensive NIH grant writing workshop. The workshop will be held April 20-21, 2020. The location
and registration site are still in development, but ORD will provide more information soon.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/arp__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AQ7nAigQ$" target="_blank"><span style="color:#0563C1">Autism Research Program</span></a><br>
<b>Clinical Trial Award</b><br>
Pre-application: April 15, 2020. Invited full application: July 16, 2020.<br>
<b>Idea Development Award</b><br>
Pre-application: April 15, 2020. Invited full application: July 16, 2020.<br>
<b>Clinical Translational Research Award</b><br>
Pre-application: April 15, 2020. Invited full application: July 16, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for April 15, 2020 pre-applications: April 1.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/ocrp__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AZ-xO1k4$" target="_blank"><span style="color:#0563C1">Ovarian Cancer Research Program</span></a><br>
<b>Clinical Translational Research Award</b><br>
Pre-application: April 23, 2020. Application: July 30, 2020.<br>
<b>Investigator-Initiated Research Award</b><br>
Pre-application: April 23, 2020. Application: July 30, 2020.<br>
<b>Ovarian Cancer Academy Award - Early Career Investigator</b><br>
Pre-application: April 23, 2020. Application: July 30, 2020.<br>
<b>Pilot Award</b><br>
Pre-application: April 23, 2020. Application: July 30, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prmrp__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AQgjzORE$" target="_blank"><span style="color:#0563C1">Peer Reviewed Medical Research Program</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Topic Areas:</span></b><span style="font-size:12.0pt;font-family:Palatino"> Arthritis, Burn Pit Exposure, Chronic Migraine and Post-Traumatic Headache, Congenital Heart Disease, Constrictive
Bronchiolitis, Diabetes, Dystonia, Eating Disorders, Emerging Viral Diseases, Endometriosis, Epidermolysis Bullosa, Familial Hypercholesterolemia, Fibrous Dysplasia, Focal Segmental Glomerulosclerosis, Food Allergies, Fragile X, Frontotemporal Degeneration,
Guillain-Barré Syndrome, Hemorrhage Control, Hepatitis B, Hydrocephalus, Immunomonitoring of Intestinal Transplants, Inflammatory Bowel Diseases, Interstitial Cystitis, Metals Toxicology, Mitochondrial Disease, Musculoskeletal Health, Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome, Myotonic Dystrophy, Nutrition Optimization, Pancreatitis, Pathogen-Inactivated Blood Products, Plant-Based Vaccines, Polycystic Kidney Disease, Pressure Ulcers, Pulmonary Fibrosis, Resilience Training, Respiratory Health, Rheumatoid Arthritis,
Sleep Disorders and Restriction, Spinal Muscular Atrophy, Sustained Release Drug Delivery, Vascular Malformation, Women’s Heart Disease<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Discovery Award</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
Pre-application (letter of intent): April 16, 2020. Application: April 30, 2020.<br>
<b>Focused Program Award</b><br>
Pre-application (preproposal): April 23, 2020. Application: August 6, 2020.<br>
<b>Investigator-Initiated Research Award</b><br>
Pre-application (preproposal): April 23, 2020. Application: August 20, 2020.<br>
<b>Technology/Therapeutic Development Award</b><br>
Pre-application (preproposal): April 23, 2020. Application: August 20, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for April 16, 2020 pre-applications: April 2.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:red"><a href="https://urldefense.com/v3/__https://www.sfari.org/grant/pilot-awards-request-for-applications/__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AaR8fUmA$" target="_blank"><span style="color:#0563C1">Simons Foundation Autism Research Initiative: Summer
2020 Pilot Award</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this
mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is
$300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due April 24, 2020.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: April 13.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-036.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AmLKXPE0$" target="_blank"><span style="color:#0563C1">Getting To Zero: Understanding HIV Viral Suppression and Transmission
in the United States (R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level
epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic
in the U.S.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for May 7, 2020 standard date: April 21.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-116.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AMwbRuXM$" target="_blank"><span style="color:#0563C1">Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01
Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA), entitled “Toward Translation of Cancer Nanotechnology Interventions (TTNCI)” is to enable the translation of nanotechnology-based cancer interventions
relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The “Toward Translation
of Nanotechnology Cancer Interventions” (TTNCI) awards are designed to mature experimental nanomedicines relying on “next-generation” nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers
that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path
towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 21, 2020; November 19, 2020; May 20, 2021; and November 18, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for May 21, 2020 deadline: May 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-20-002.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A5Bl0hk4$" target="_blank"><span style="color:#0563C1">Supporting Primary Care to Advance Cardiovascular Health in States
with High Prevalence of Preventable CVD Events (U18)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Agency for Healthcare Research and Quality (AHRQ) seeks applications to disseminate and implement patient-centered outcomes research (PCOR) findings directly to primary care practices
and support practices in implementing PCOR clinical and organizational findings. Applicants are expected to develop sustainable, State-based quality improvement support capacity through partnership with State and local organizations, build and engage a network
of primary care practices, disseminate PCOR findings on heart health, and increase the capacity of primary care practices to implement evidence in the future.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 22, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 11.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-063.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AvYC5E5s$" target="_blank"><span style="color:#0563C1">NIAID Resource-Related Research Projects (R24 Clinical Trial
Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related
Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support
development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support
from the NIAID are not appropriate.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the
mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious,
immune-mediated, and allergic diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires January 8, 2023.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-126.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_APo5I9Yo$" target="_blank"><span style="color:#0563C1">NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not
Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database bioinformatics resources that are of
major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the resource, user training and services, provision of community-generated data
storage and archiving, wide dissemination of the tools and/or resources, and establishment of interoperability with other NIH bioinformatics resources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-104.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_Acy1R4TE$" target="_blank"><span style="color:#0563C1">Biomedical Technology Development and Dissemination Center (RM1 – Clinical
Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Development and Dissemination (BTDD) Centers. The BTDD program supports the
development of technologies once their feasibility has been established and the dissemination of these technologies to the wider biomedical research community. The program encourages investigators to propose projects that address any of the biomedical research
areas within the <a href="https://urldefense.com/v3/__http://www.nigms.nih.gov/about/overview/__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_Ag33jlY8$"><span style="color:#0563C1">mission of NIGMS</span></a>. The Centers are required to make their technologies available to the research community in a sustainable manner, to provide user training,
and to disseminate the Center’s technologies and results. Centers should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Potential applicants are strongly encouraged to contact
NIGMS staff at least 10 weeks prior to the application due date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 26, 2020; January 26, 2021; May 26, 2021; January 26, 2022; May 26, 2022; and January 26, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 26, 2020 deadline: May 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-103.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AxPAohGs$" target="_blank"><span style="color:#0563C1">Collaborative Program Grant for Multidisciplinary Teams (RM1 – Clinical
Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that
are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable
with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate
for this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 27, 2020; January 27, 2021; May 27, 2021; January 27, 2022; May 27, 2022; and January 27, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 27, 2020 deadline: May 13.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">NIH S10s: Shared Instrumentation Grant (SIG) Program, High-End Instrumentation (HEI) Grant Program, Shared Instrumentation for Animal Research (SIFAR) Grant Program<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-113.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AeCrroB4$" target="_blank"><span style="color:#0563C1">SIG</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially
available instruments or integrated systems. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass
spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-114.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A1vRBC0I$" target="_blank"><span style="color:#0563C1">HEI</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially
available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffractometers,
mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, high throughput robotic screening systems, and biomedical imagers.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-112.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_ASL7sNcY$" target="_blank"><span style="color:#0563C1">SIFAR</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary
to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined
area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies
needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000,
after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 1, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-053.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_ANFnVtrQ$" target="_blank"><span style="color:#0563C1">Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived
Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their
cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried
in these vesicles.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.
</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 / R01 Clinical Trials Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-082.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A6fAYfb0$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-055.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_Ai1dS2n4$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements encourage research grant applications directed toward developing next-generation human cell-derived microphysiological systems and related assays
that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease
states.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Co-infection and Cancer (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-061.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AfjWky_0$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-062.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AMiDQdTo$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of these Funding Opportunity Announcements is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined
as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference
will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires January 8, 2023.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"> </span><span style="font-size:12.0pt;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-064.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_Ax9xFu5I$" target="_blank"><span style="color:#0563C1">Archiving and Documenting Child Health and Human Development
Data Sets (R03 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the
<i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires January 8, 2023.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"> </span><span style="font-size:12.0pt;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-068.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A_ulFMdA$" target="_blank"><span style="color:#0563C1">Improving Quality of Care and Patient Outcomes During Care
Transitions (R01)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable,
and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to produce health services
research that will rigorously test promising interventions aimed at improving communication and coordination during care transitions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires December 6, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-070.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AagFZ3IQ$" target="_blank"><span style="color:#0563C1">Research Infrastructure Development for Interdisciplinary Aging Studies
(R21/R33 – Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or
collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will
develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires November 17, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-071.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AE1HeT3k$" target="_blank"><span style="color:#0563C1">Advanced-Stage Development and Utilization of Research Infrastructure
for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring
interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either
through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires November 17, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-004.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AQWZSIVw$" target="_blank"><span style="color:#0563C1">Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical
Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant).
Adjuvants that are combined in these studies must already have shown individual immune modulating activity.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components
for vaccines tailored to specific pathogens.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID’s overall adjuvant research objectives. The long-term goal is to promote the development
of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 29, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: June 16.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-006.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AgVD080I$" target="_blank"><span style="color:#0563C1">Alzheimer’s Disease Sequencing Project Functional Genomics Consortium
(U01 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically
discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer’s disease and related dementias (AD/ADRD).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 1, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: June 18.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-at-21-002.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_Amyv6C7k$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-21-001.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AryheUuk$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate
the activities of glymphatic/lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may
be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 9, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: June 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-004.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AAkTape8$" target="_blank"><span style="color:#0563C1">Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication,
latency, or pathogenesis in the context of substance use disorders (R21 / R33 Clinical Trial Not Allowed)
</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis
in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis
(including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 20, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: July 7.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-016.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A50G651Y$" target="_blank"><span style="color:#0563C1">Planning Projects for Clinical Trials on Effects of Sustained Reductions
in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional)
</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) invites applications for 3-year planning projects for trials in either of two age ranges (25 to <50 or ≥50 years of age) to determine the effects
of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. Proposed
projects must plan for trials with a minimum of three arms: a control group; a CR group; and at least one other nutritional intervention that modifies level, timing, or composition of nutrient intake. Narrower age ranges within the younger and older age groups
may be proposed. The projects will support organizational, planning, and protocol development activities, addressing elements such as selection and design of interventions, recruitment, eligibility criteria, selection of pre-specified study outcomes, outcome
ascertainment, behavioral interventions to achieve and maintain adherence, adherence measurement, and outcome analysis. The projects will also support pilot studies and data analyses needed for these planning activities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 23, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: July 13. </span>
</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-010.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_AyS7dDVU$" target="_blank"><span style="color:#0563C1">Research Education Program Grants for CryoEM and CryoET Curriculum
Development (R25 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational
activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary
focus on: <b>Curriculum or Methods Development</b>. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron
tomography (cryoET) for structural and cell biology research. Technical advances in cryoEM have resulted in its expanded use in generating reliable atomic models of complete and fully functional macromolecular complexes. An emerging related cryoEM method,
cryoET, can image macromolecular assemblies in intact unstained frozen cells in three dimensions (3-D). Together, these methods enable high-resolution analysis of previously inaccessible levels of biological organization, ranging from below 100 kD to whole
cells. Currently, demand for existing training opportunities exceeds capacity. Moreover, this demand is expected to rise as adoption of cryoEM and cryoET technology continues to increase. To accomplish the stated over-arching goal, this FOA will support creative
educational activities with a primary focus on addressing instructional needs for new users of cryoEM and cryoET methods by supporting the development of online and computer-based instructional materials in these technologies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 24, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: July 13.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-122.html__;!!PhOWcWs!ltKg9iLd-BoTV9cSCRMw_gTp6Dbn9yKnPiPfwX46ZEswkwdb2pTzDENMWjgiuZvnm_pLRI5uZV_A8IElqM0$" target="_blank"><span style="color:#0563C1">Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery
and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects
into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition,
applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including
under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through
Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee
Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 11, 2020; February 9, 2021; August 10, 2021; February 9, 2022; August 9, 2022; and February 9, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for August 11, 2020 deadline: July 29.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>